COLLEGIUM PHARMACEUTICAL, INC. Annual Report: An Investor's Guide

This report offers a clear and concise overview of COLLEGIUM PHARMACEUTICAL, INC.'s financial performance and strategic direction for the past fiscal year, tailored for retail investors.

1. Business Overview

COLLEGIUM PHARMACEUTICAL, INC. is a specialty pharmaceutical company that develops and sells innovative products for pain management and other central nervous system disorders. Its core product portfolio includes:

• Belbuca (buprenorphine buccal film)
• Xtampza ER (oxycodone extended-release)
• Jornay PM (methylphenidate extended-release for ADHD)
• The Nucynta line (tapentadol immediate-release and extended-release)
• Symproic (naldemedine) for opioid-induced constipation

The past year saw COLLEGIUM significantly expand its strategic footprint. In early 2024, the company acquired Ironshore Pharmaceuticals, Inc., substantially broadening its ADHD franchise with Jornay PM. This move followed the successful integration of BioDelivery Sciences International (BDSI) in late 2023, which added Belbuca to COLLEGIUM's portfolio and significantly boosted its presence in pain management. These acquisitions were central to the company's growth strategy, allowing it to leverage its existing commercial infrastructure across a wider product base. COLLEGIUM operates as a single business segment, reflecting its integrated approach to product development and commercialization.

2. Financial Performance

COLLEGIUM PHARMACEUTICAL, INC. reported total revenues of approximately $550 million for the fiscal year, marking a 15% increase year-over-year. This growth primarily stemmed from Belbuca's strong performance and Jornay PM's initial contributions after the Ironshore acquisition. Net income reached $75 million, or $2.50 per diluted share, up from $60 million, or $2.00 per diluted share, in the prior year. This demonstrates improved profitability despite acquisition-related expenses. Gross margin remained robust at approximately 80%, reflecting the high value of its pharmaceutical products.

Key product sales highlights include:

• Belbuca: Over $200 million
• Xtampza ER: $150 million
• Jornay PM: Quickly reached $50 million in sales post-acquisition

3. Risk Factors

• Customer Concentration Risk: A few large pharmaceutical wholesalers and pharmacy chains account for a significant portion of COLLEGIUM's net product sales and accounts receivable. For example, Customer One generated approximately 35% of gross sales. Losing or seeing a significant reduction in purchases from any of these key customers could materially impact revenues and profitability.
• Litigation and Intellectual Property Risk: Numerous ongoing patent infringement and commercial lawsuits pose significant financial and operational risks. Adverse outcomes could result in substantial monetary damages, loss of product exclusivity, or injunctions preventing sales, particularly for key revenue drivers like Xtampza ER and Belbuca.
• Regulatory and Market Risks: Operating in the pharmaceutical industry, especially within pain management, exposes COLLEGIUM to intense regulatory scrutiny, evolving healthcare policies, and public perception challenges related to the opioid crisis. Generic competition for its products, once patent protection expires, also presents a significant long-term risk to market share and pricing power.
• Acquisition Integration Risk: While the Ironshore and BDSI acquisitions are strategic, failing to fully integrate operations, realize anticipated synergies, or retain key talent could hinder expected financial benefits and operational efficiency.

4. Management Discussion (MD&A Highlights)

This section provides management's perspective on the company's financial condition and results of operations, highlighting key factors that influenced performance during the fiscal year.

Results of Operations: As detailed in the Financial Performance section, the company achieved significant revenue growth, primarily driven by strategic acquisitions and the strong performance of key products like Belbuca and Xtampza ER. Profitability improved year-over-year despite acquisition-related expenses, reflecting effective cost management and robust gross margins.

Major Achievements & Challenges: The fiscal year saw COLLEGIUM successfully acquire and integrate Ironshore Pharmaceuticals and BioDelivery Sciences International, significantly expanding its product portfolio and market reach in pain management and ADHD. The company also actively returned capital to shareholders through share repurchase programs, buying back approximately $100 million of common stock, including an Accelerated Share Repurchase (ASR) program. Challenges included navigating a complex litigation landscape, particularly patent infringement cases related to Xtampza ER and Belbuca, and managing the inherent risks associated with integrating acquired companies.

Strategic Direction: COLLEGIUM's strategy focuses on growth through targeted acquisitions that expand its product portfolio and leverage its commercial infrastructure, alongside a commitment to returning capital to shareholders. The company continues to prioritize operational efficiency and pipeline development to sustain long-term growth.

Market Trends & Regulatory Environment: The pharmaceutical industry, particularly pain management, continues to face significant trends. The ongoing opioid crisis has led to increased regulatory scrutiny, stricter prescribing guidelines, and a push towards abuse-deterrent formulations, which COLLEGIUM's products like Xtampza ER are designed to address. Healthcare policy changes, including drug pricing pressures and reimbursement reforms, also pose potential challenges. In the ADHD market, evolving diagnostic criteria and treatment paradigms influence product demand. COLLEGIUM closely monitors these trends, adapting its commercial strategies and product development efforts to align with the dynamic regulatory and market landscape.

Liquidity and Capital Resources: As discussed in the Financial Health section, the company maintains a healthy financial position with adequate cash, investments, and access to credit facilities to manage its obligations and fund future growth, despite increased debt from acquisitions.

Critical Accounting Policies and Estimates: The company prepares its financial statements in accordance with U.S. GAAP, requiring management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. Key areas involving significant estimates typically include revenue recognition, valuation of intangible assets and goodwill, litigation reserves, and stock-based compensation.

Off-Balance Sheet Arrangements: The company does not have any significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

5. Financial Health

COLLEGIUM maintains a healthy financial position with cash and cash equivalents of approximately $120 million and a diversified investment portfolio totaling $80 million, including money market funds, corporate debt, and U.S. government securities.

The company's debt structure includes:

• 2.625% Convertible Senior Notes due 2026: Approximately $175 million outstanding. These notes offer financial flexibility but could dilute equity if converted.
• 2.875% Convertible Senior Notes due 2029: Approximately $250 million outstanding, issued to support strategic initiatives.
• Term Loans: A 2022 Term Loan with an outstanding balance of $100 million and a 2024 Term Loan of $300 million, primarily used to finance the Ironshore acquisition.
• 2025 Credit Agreement: Provides a $150 million revolving credit facility (undrawn as of year-end) and a delayed draw term loan, enhancing liquidity and operational flexibility.

Despite increased debt from acquisitions, the company's strong cash flow from operations and diversified investment strategy provide adequate liquidity to manage its obligations and fund future growth.

6. Future Outlook

COLLEGIUM anticipates continued revenue growth in the upcoming fiscal year, projecting total revenues between $600 million and $630 million. This growth will be driven by the full-year impact of the Ironshore acquisition and sustained performance from its core products. The company plans to focus on optimizing the integration of its acquired assets, expanding market penetration for Jornay PM, and managing its debt obligations. It also expects to continue investing in lifecycle management for existing products and exploring potential new business development opportunities to further diversify its portfolio. Management remains committed to disciplined capital allocation and enhancing shareholder value.

7. Competitive Position

COLLEGIUM operates in highly competitive markets for pain management and ADHD. In pain management, products like Xtampza ER and Belbuca compete with other branded and generic opioid and non-opioid pain medications, including abuse-deterrent formulations. Jornay PM competes within the stimulant market for ADHD, facing established brands and generics. COLLEGIUM differentiates itself by focusing on abuse-deterrent technologies and unique drug delivery systems. This strategy aims to capture market share by offering differentiated product profiles that address specific patient needs and safety concerns. The company leverages a specialized sales force and strong relationships with prescribers in its target therapeutic areas.